Differences in biomarker testing in non-small cell lung cancer: real-world outcomes within an integrated healthcare system
Biomarker testing prevalence was higher in advanced stage NSCLC as expected, with decreased 3-year mortality in patients who received NGS testing. Our findings in a large real-world diverse population suggest that broader uptake of comprehensive biomarker testing across all stages of NSCLC is warranted for improved outcomes.
Authors
- Jeffrey B. Velotta (ORCID: https://orcid.org/0000-0002-1405-8487)
- Nathan J. Alcasid (ORCID: https://orcid.org/0000-0002-0016-8474)
- Lori C. Sakoda (ORCID: https://orcid.org/0000-0002-0900-5735)
- Wendy Dyer (ORCID: https://orcid.org/0000-0002-8861-5549)
- Kenneth M. Williams (ORCID: https://orcid.org/0000-0001-9416-2307)
- Varada Sarovar (ORCID: https://orcid.org/0009-0005-1860-5133)
- William Carroway
- Huyun Dong
- Jingrong Yang (ORCID: https://orcid.org/0000-0003-1061-560X)
Institutions
- Kaiser Permanente (US)
- University of California, San Francisco (US)
- California State University, East Bay (US)
- East Bay Educational Collaborative (US)
- University of San Francisco (US)
Publication Details
- Journal
- Frontiers in Surgery
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fsurg.2025.1632360
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca